^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    LRRK2 inhibitor

    Related drugs:
    1d
    NEULARK: A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (clinicaltrials.gov)
    P2, N=150, Recruiting, Neuron23 Inc. | Trial completion date: Sep 2027 --> Jun 2028 | Trial primary completion date: Sep 2026 --> Dec 2027
    Trial completion date • Trial primary completion date • Companion diagnostic
    |
    LRRK2 (Leucine Rich Repeat Kinase 2)
    13d
    LUMA: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 (clinicaltrials.gov)
    P2, N=650, Completed, Biogen | Active, not recruiting --> Completed
    Trial completion
    14d
    Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Denali Therapeutics Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2026 --> Mar 2027
    Enrollment closed • Trial primary completion date
    |
    LRRK2 (Leucine Rich Repeat Kinase 2)
    2ms
    A Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of Orally Administered ZE75-0267 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of ZE75-0267 in Healthy Volunteers (ACTRN12624001426572)
    P1, N=96, Recruiting, Brenig Therapeutics AU Pty Ltd. (subsidiary of Brenig Therapeutics ) | N=64 --> 96
    Enrollment change • First-in-human
    4ms
    Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers (clinicaltrials.gov)
    P2, N=112, Not yet recruiting, Halia Therapeutics, Inc.
    New P2 trial
    |
    APOE (Apolipoprotein E)
    5ms
    ALK Inhibition Prolongs Survival in a Mouse Model of ALK-Positive Anaplastic Thyroid Cancer. (PubMed, Thyroid)
    Treatment of primary Trp53KO/ALKF1174L ATC cells with the ALK inhibitor TAE-684 decreased AKT and ERK phosphorylation and induced a dose-dependent cytotoxicity...This study provides the first functional data supporting the use of ALK inhibitors in patients with ALK-driven ATC. Our novel ATC mouse model and the derived cell lines offer valuable tools to explore the molecular characteristics of ATC, especially signaling pathway activation and tumor microenvironment, and to test novel therapeutics for the treatment of advanced thyroid cancers.
    Preclinical • Journal
    |
    ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53)
    |
    TP53 mutation • ALK positive • ALK rearrangement
    |
    TAE-684
    9ms
    Restoration of Lysosomal Hydrolase Activities by LRRK2 Inhibition in GBA1- and LRRK2-Associated Parkinson's Disease Patient-Derived Cells. (PubMed, J Neurochem)
    Moreover, LRRK2 inhibition also enhances the activity of other lysosomal hydrolases. Our findings expand the understanding of the molecular mechanism of LRRK2 inhibitors, offering valuable insights for further development of PD treatments.
    Journal
    |
    CTSD (Cathepsin D) • LAMP2 (Lysosomal Associated Membrane Protein 2) • LRRK2 (Leucine Rich Repeat Kinase 2)
    9ms
    Identification of biomarkers based on ubiquitin-correlated genes for predicting immune profile and drug sensitivity in lung adenocarcinoma. (PubMed, Front Pharmacol)
    The medications TAE684, Cisplatin, and Midostaurin exhibited the largest negative correlation with Riskscore, according to drug sensitivity study. Lastly, we demonstrated through in vitro tests that HEATR1 knockdown markedly reduced LUAD cell survival, migration, and invasion. This study is the first to systematically integrate the ubiquitin pathway with multi-omics data, constructing a robust risk model for LUAD prognosis and immune characteristics, providing a theoretical reference for future exploration of potential biomarkers for LUAD patients' diagnosis.
    Journal • IO biomarker
    |
    FAT1 (FAT atypical cadherin 1)
    |
    cisplatin • midostaurin • TAE-684
    11ms
    SLC34A2 inhibits tumorigenesis and progression via upregulating LRRK2/TTF-1/SELENBP1 axis in lung adenocarcinoma. (PubMed, Cancer Gene Ther)
    In summary, our current research revealed a novel SLC34A2/LRRK2/TTF-1/SELENBP1 axis and its involvement in inhibiting the malignant characteristics of LUAD cells for the first time, which made contribution to further exploring the clinical application of SLC34A2. Furthermore, it also might offer novel insights into understanding how AT2 cells undergo malignant transformation into LUAD cells in the future.
    Journal
    |
    SLC34A2 (Solute carrier family 34 member 2) • TTF1 (Transcription Termination Factor 1) • NKX2-1 (NK2 Homeobox 1) • LRRK2 (Leucine Rich Repeat Kinase 2)
    1year
    Study to Evaluate HT-4253 in Healthy Subjects (clinicaltrials.gov)
    P1, N=80, Completed, Halia Therapeutics, Inc. | Recruiting --> Completed
    Trial completion
    1year
    LUMA: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 (clinicaltrials.gov)
    P2, N=650, Active, not recruiting, Biogen | Recruiting --> Active, not recruiting
    Enrollment closed
    1year
    A Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of Orally Administered ZE75-0267 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of ZE75-0267 in Healthy Volunteers (ACTRN12624001426572)
    P1, N=64, Recruiting, Brenig Therapeutics AU Pty Ltd. (subsidiary of Brenig Therapeutics ) | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date